SummitIn person

10th Dermatology Drug Development Summit

Name: 10th Dermatology Drug Development Summit
Start: 2026-11-03
End: 2026-11-05
Location: The Colonnade Boston

Hosted by Hanson Wade

3 – 5 November 2026
Add to calendar
Apple / Outlook (.ics)Google Calendar
Welcome to kongre.net
Events Categories News Jobs Event partners
The Colonnade Boston, Boston, United States of America
Clinical MedicineDermatologyHealth SciencesPharmacy & Pharmaceutical Sciences

Let others know you'll be there. This does not register you for the event.

Welcome to kongre.net

Official website

Programme

Published

40 sessions across 3 days

2 rooms · 33 speakers

Browse programme

Call for Papers

Submissions are handled by the organiser

View submission details

Registration

Registration is handled by the organiser

Fees are listed on this page

View registration details

Key facts

10th Dermatology Drug Development Summit is a summit held 3 – 5 November 2026 in The Colonnade Boston, Boston, United States of America, organised by Hanson Wade.

Dates:: 3 – 5 November 2026
Format:: In person
Venue:: The Colonnade Boston, Boston, United States of America
Subjects:: Dermatology, Pharmacy & Pharmaceutical Sciences
Organiser:: Hanson Wade
Official website:: dermatology-drugdevelopment.com

The 10th Dermatology Drug Development Summit is the premier annual forum dedicated to advancing the discovery, preclinical development, clinical strategy, and commercialization of next-generation therapies for rare and common inflammatory skin diseases. Organised by Hanson Wade, the event takes place in Boston, MA from November 3 to 5, 2026. Bringing together over 90 senior leaders from leading pharmaceutical and biotech organizations, the summit provides a distinctive platform to benchmark emerging science, evaluate novel therapeutic targets, optimize dosing regimens, and share practical insights across dedicated discovery, preclinical, clinical, and commercial tracks.

Conference theme

Deciphering Disease Heterogeneity, Optimizing Dosing Regimens & De-Risking Emerging Targets to Transform Long-Term QoL & Address Unmet Needs Across Rare & Common Inflammatory Skin Disease

Topics

Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Vitiligo, Alopecia Areata, Acne, Epidermolysis Bullosa, Prurigo Nodularis, Molluscum Contagiosum, AI-enabled target discovery, translational de-risking, biomarker development, next-generation modalities, dosing optimization, clinical differentiation, and commercialization strategy.

Who should attend

Leaders in discovery, translational medicine, preclinical development, clinical strategy, medical affairs, and commercial functions from pharmaceutical, biotech, academic, and solution provider organizations.